Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
- the LEAP-017 Investigators
- National Cancer Center Japan
- Sun Yat-Sen University
- Complutense University
- Rambam Health Care Campus-Oncology
- Veterans General Hospital-Taipei
- National Yang Ming Chiao Tung University
- The University of Chicago
- Istanbul Medeniyet University
- University of Copenhagen
- North York General Hospital
- University of Ulsan
- University College Hospital
- Instituto de Investigaciones Metabólicas
- Peter Maccallum Cancer Centre
- Leningrad Regional Clinical Oncology Dispensary
- MSD China
- Merck
- Ludwig Maximilian University of Munich
- Vall d'Hebron Institute of Oncology
Research output: Contribution to journal › Article › peer-review
67
Link opens in a new tab
Scopus
citations